Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCampos Martinez, Carolina
dc.contributor.authorSaubí Roca, Narcís
dc.contributor.authorRodríguez Frias, Francisco
dc.contributor.authorRando Segura, Ariadna
dc.contributor.authorColomer-Castell, Sergi
dc.contributor.authorGarcia-Cehic, Damir
dc.contributor.authorParés-Badell, Oleguer
dc.contributor.authorADOMBI, Caroline Mélanie
dc.contributor.authorQUER, JOSEP
dc.contributor.authorPiñana, María
dc.contributor.authorGonzález-Sánchez, Alejandra
dc.contributor.authorEsperalba, Juliana
dc.contributor.authorCodina, María Gema
dc.contributor.authorPumarola Suñe, Tomàs
dc.contributor.authorGregori Font, Josep
dc.contributor.authorEsteban Mur, Juan Ignacio
dc.contributor.authorBORRAS BERMEJO, BLANCA
dc.contributor.authorIbañez Lligoña, Marta
dc.contributor.authorAntón Pagarolas, Andrés
dc.contributor.authorAndrés Vergés, Cristina
dc.date.accessioned2023-02-01T12:55:58Z
dc.date.available2023-02-01T12:55:58Z
dc.date.issued2022-12-29
dc.identifier.citationCampos C, Colomer-Castell S, Garcia-Cehic D, Gregori J, Andrés C, Piñana M, et al. The frequency of defective genomes in Omicron differs from that of the Alpha, Beta and Delta variants. Sci Rep. 2022 Dec 29;12:22571.
dc.identifier.issn2045-2322
dc.identifier.urihttps://hdl.handle.net/11351/8945
dc.descriptionEvolution; Genetics; Molecular biology
dc.description.abstractThe SARS-CoV-2 Omicron variant emerged showing higher transmissibility and possibly higher resistance to current COVID-19 vaccines than other variants dominating the global pandemic. In March 2020 we performed a study in clinical samples, where we found that a portion of genomes in the SARS-CoV-2 viral population accumulated deletions immediately before the S1/S2 cleavage site (furin-like cleavage site, PRRAR/S) of the spike gene, generating a frameshift and appearance of a premature stop codon. The main aim of this study was to determine the frequency of defective deletions in prevalent variants from the first to sixth pandemic waves in our setting and discuss whether the differences observed might support epidemiological proposals. The complete SARS-CoV-2 spike gene was deeply studied by next-generation sequencing using the MiSeq platform. More than 90 million reads were obtained from respiratory swab specimens of 78 COVID-19 patients with mild infection caused by the predominant variants circulating in the Barcelona city area during the six pandemic waves: B.1.5, B.1.1, B.1.177, Alpha, Beta, Delta, and Omicron. The frequency of defective genomes found in variants dominating the first and second waves was similar to that seen in Omicron, but differed from the frequencies seen in the Alpha, Beta and Delta variants. The changing pattern of mutations seen in the various SARS-CoV-2 variants driving the pandemic waves over time can affect viral transmission and immune escape. Here we discuss the putative biological effects of defective deletions naturally occurring before the S1/S2 cleavage site during adaption of the virus to human infection.
dc.language.isoeng
dc.publisherNature Portfolio
dc.relation.ispartofseriesScientific Reports;12
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCOVID-19 (Malaltia) - Vacunació
dc.subjectImmunoglobulines
dc.subject.meshCoronavirus Infections
dc.subject.meshViral Vaccines
dc.subject.meshAntibodies, Neutralizing
dc.titleThe frequency of defective genomes in Omicron differs from that of the Alpha, Beta and Delta variants
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1038/s41598-022-24918-8
dc.subject.decsinfecciones por Coronavirus
dc.subject.decsvacunas víricas
dc.subject.decsanticuerpos neutralizantes
dc.relation.publishversionhttps://doi.org/10.1038/s41598-022-24918-8
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Campos C, Quer J] Grup de Recerca de les Malalties Hepàtiques, Unitat Hepàtica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Colomer-Castell S] Grup de Recerca de les Malalties Hepàtiques, Unitat Hepàtica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Garcia-Cehic D, Gregori J] Grup de Recerca de les Malalties Hepàtiques, Unitat Hepàtica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. [ndrés C, Piñana M, González-Sánchez A, Esperalba J, Codina MG, Rando-Segura A, Saubí N] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Borràs B, Parés-Badell O] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Medicina Preventiva, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Adombi CM, Ibañez-Lligoña M] Grup de Recerca de les Malalties Hepàtiques, Unitat Hepàtica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Esteban JI] Grup de Recerca de les Malalties Hepàtiques, Unitat Hepàtica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Rodriguez-Frías F] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Pumarola T, Antón A] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid36581627
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/RD16%2F0016%2F0003
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record